Untangling Sarepta's Gene Therapy Fallout and Trust Deficit on August 04, 2025 AAVrh74 vector clinical holds Elevidys gene therapy Muscular Dystrophies, Limb-Girdle Muscular Dystrophy, Duchenne patient deaths Regulatory Action Translucent United States Food and Drug Administration +
Lack of Transparency Tarnishes Sarepta's Sheen as Patient Deaths Trigger FDA Battle on July 23, 2025 Elevidys gene therapy lack of transparency Market Muscular Dystrophies, Limb-Girdle Muscular Dystrophy, Duchenne patient deaths Regulatory Action United States Food and Drug Administration Withdraw (activity) +
Sarepta Stands Ground Against HHS Request To Stop Elevidys Shipments on July 21, 2025 AAVrh74 CHARGE Syndrome drug safety Elevidys gene therapy Muscular Dystrophy, Duchenne patient deaths Regulatory Action Ships Suspensions United States Food and Drug Administration +